Therefore, the Phase III LibiGel (testosterone gel) safety study will continue as per the FDA-agreed protocol, without modifications including continued enrollment of new subjects.
FORBES: BioSante's Pollyannish Press Release
应用推荐
模块上移
模块下移
不移动